Skip to Content Facebook Feature Image

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

Business

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026
Business

Business

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

2026-11-18 06:00 Last Updated At:06:15

MADRID, Nov. 18, 2026 /PRNewswire/ -- Gene Solutions hosted its first Global Industry Satellite Symposium, sharing multi-omic liquid biopsy technologies and the clinical and real-world data generated in Asia with the international oncology community. The achievement reflects the company's evolution from an Asia-based genetic testing pioneer to a globally engaged innovator of cell-free DNA technologies spanning cancer screening, precision oncology, and functional applications.

ESMO Congress, one of the world's leading oncology meetings, brought together more than 40,000 participants from the global cancer community in Madrid in 2026 for the largest congress in ESMO's history. The meeting provided a platform for scientific exchange on advances in precision oncology.

The symposium, titled "AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation," was attended at full capacity and convened internationally recognized experts, including Prof. Umberto Malapelle, President of the International Society of Liquid Biopsy and Professor at the University of Naples Federico II; Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong; Prof. Aya El Helali of The University of Hong Kong; Dr. Le Son Tran and Dr. Vien Le of the Medical Genetics Institute; and Asst. Prof. Lucksamon Thamlikitkul of Siriraj Hospital, Mahidol University.  

The program reviewed multi-omic technologies and evidence from Asia, encompassing both prospective clinical studies and real-world datasets. Sessions focused on challenges and future directions in multi-cancer early detection, comprehensive genomic and transcriptomic profiling, longitudinal ctDNA monitoring, and immune profiling as well as functional patient-derived organoid models for evaluating treatment response to support therapeutic decision-making.

Discussions across the presentations highlighted the value of integrating complementary multi-omic approaches rather than relying on any single technology. Drawing on clinical validation and real-world experience generated in Asia, Gene Solutions' patient-centered ecosystem was highlighted, connecting earlier detection, comprehensive genomic profiling, deeper biological and immune understanding, functional investigation of treatment response, and longitudinal circulating tumor DNA monitoring around the needs of the same patient. The approach is intended to support more individualized care while addressing the practical requirements of implementation across diverse healthcare settings.

Reflecting on the symposium discussions, Prof. Umberto Malapelle, President of the International Society of Liquid Biopsy, emphasized the growing significance of multi-cancer early detection:

"We discussed how the cancer-screening landscape is evolving and the potential role of multi-cancer early detection. MCED assays represent one of the key weapons in this battle against cancer. The technology is now available, promising data are emerging from different settings, and the next step is to generate the prospective evidence needed to demonstrate clinical utility and support appropriate implementation."

Beyond early detection, symposium discussions also addressed how advanced molecular technologies can be translated into routine cancer care across diverse healthcare systems.

As Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong commented:

"Liquid biopsy can extend access to accurate genomic profiling in settings where access to tissue-based testing may be limited. Combining liquid and tissue approaches improves the completeness of molecular information available for monitoring, diagnosis, and treatment selection, while generating data that may be relevant beyond the Asian region."

The symposium also highlighted how precision oncology is evolving beyond genomic alterations alone toward a more comprehensive understanding of disease biology.

Prof. Aya El Helali of The University of Hong Kong said:

"Precision oncology increasingly requires a multilayered understanding of disease, integrating genomic, transcriptomic, epigenetic, proteomic, and immune-related information. Bringing these insights together with functional models such as patient-derived organoids may help prioritize more individualized and evidence-driven treatment strategies."

Gene Solutions and the Medical Genetics Institute also contributed two posters presenting real-world research from Southeast Asia on tissue and liquid-biopsy molecular profiling and longitudinal ctDNA monitoring across multiple cancer types.

Beyond the scientific program, the company's exhibition area facilitated discussions with oncologists, molecular pathologists, translational researchers, laboratory leaders, healthcare institutions, pharma and industry colleagues throughout the conference.

Commenting on Gene Solutions' participation at ESMO Congress 2026, Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, said:

"The discussions underscored both the progress made in applying multi-omic liquid biopsy approaches in clinical practice and the remaining challenges in supporting broader access. Our focus remains on advancing technologies that can deliver clinically useful information — from earlier detection to treatment selection and disease monitoring — across different healthcare settings."

For Gene Solutions, ESMO Congress 2026 represented more than a successful scientific event. It marked an important step in a journey that began in Asia and continues to grow through a commitment to innovations that support earlier cancer detection, more precise treatment decisions, deeper biological understanding, and more effective disease monitoring for patients worldwide.

Watch the faculty presentations and interviews, view the panel discussion, and explore Gene Solutions' scientific posters at: https://www.genesolutions.com/inside-gene-solutions-esmo-2026-symposium-and-scientific-program-six-perspectives-across-the-cancer-care-continuum/

About Gene Solutions

Gene Solutions is a global biotechnology company advancing precision cell-free DNA solutions across cancer detection (SPOT-MAS), precision oncology (K-TRACK, K-4CARE), and pregnancy care (triSure). By combining multi-omic science, data intelligence and a scalable technology platform, Gene Solutions brings world-class genomics closer to clinicians and patients, expanding access to clinically meaningful innovation around the world.

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

Compact 6-inch end user devices combine fully rugged reliability, powerful edge intelligence and seamless connectivity for enhanced situational awareness in challenging defence environments

News in brief:

  • Getac's new 6-inch MX60 and MX60W are purpose-built for the specific needs of defence personnel operating in the field.
  • Both devices are designed to integrate seamlessly into the heart of modern ATAK (MX60) and WINTAK (MX60W) soldier systems.
  • Getac's range of secure hands-free carrying options, including optional tactical vest and wrist mounts, further enhances mobility and versatility in challenging environments.

TAIPEI, Nov. 18, 2026 /PRNewswire/ -- Getac Technology Corporation (Getac), a leading provider of rugged computing and mobile video solutions and a manufacturer with advanced in-house capabilities, today announced the launch of its new MX60 and MX60W end user devices (EUDs).

The MX60 will be offered in two Android configurations: Android 15 without Google Mobile Services (Non-GMS), available at launch, and Android 17 with GMS, expected to follow shortly after launch. The MX60W runs Windows 11 IoT Enterprise LTSC. Both EUDs are designed to integrate with ATAK (MX60) and WINTAK (MX60W) soldier systems, providing real-time situational awareness and tactical intelligence to operators in the field.

Edge intelligence for faster decisions
Powered by Qualcomm's QCS6490 chipset – built on the energy-efficient Arm®v8 64-bit architecture – the MX60 and MX60W deliver up to 13 TOPS of on-device AI performance through the integrated Qualcomm AI Engine, enabling AI workloads to be processed locally for faster decisions at the tactical edge, while long battery life supports extended use between charges. A 6-inch FHD+ LumiBond display offers 1,000 nits of brightness with Getac sunlight readable technology and can dim down to 0.6 nits for low-light and night operations. Combined with a glove-enabled capacitive touchscreen, it delivers clear legibility in changeable weather conditions, while dedicated L1/L5 GPS lets users calculate positions quickly and accurately for faster, more informed decision making in the field.

Seamless connectivity across the integrated soldier system

The MX60 and MX60W are designed to support information exchange within the integrated soldier system. Featuring Wi-Fi 6E and Bluetooth 5.2, the devices support reliable wireless connectivity with tactical hubs and peripheral devices, enabling real-time information sharing, and facilitating command and control (C2) interoperability and uncrewed system integration. Both EUDs feature an integrated USB 3.2 Gen 1 Type-C port, supporting connectivity with various tactical peripherals and interfaces through compatible cables and adapters, while a MicroSD (MX60) or smart card reader (MX60W) adds flexibility as needed.

Built for efficient mission execution

The MX60 and MX60W offer outstanding mobility in the field. Weighing just 410g, they can be carried and operated for extended periods of time, while optional tactical vest and wrist mounts enable hands-free operations.

Both devices are built to thrive in the harsh operational environments often encountered by frontline operators. MIL-STD-810H and IP67 certifications, together with 6ft (1.8m) drop resistance, provide rugged protection against spillages, drops, bumps, shocks, dust, vibration and more, while a wide operating temperature range of -21°C to 63°C (-5.8°F to 145°F) adds confidence in extreme conditions. The devices are also MIL-STD-461G certified for electromagnetic compatibility, an important consideration when operating alongside radios and other critical electronics.

Functionality meets security

The MX60 and MX60W are designed with real-world functionality in mind. Multiple programmable buttons give operators instant, one-press access to key functions, keeping their focus on the mission rather than on-screen menus, even in gloved or wet conditions.

For enhanced data security, Getac's Secure Erase function allows users to permanently delete all data stored on the device if needed, helping prevent sensitive information from reaching unintended or inappropriate parties.

"Modern defence is increasingly defined by information. Mission success depends on how quickly data can move from sensor to soldier to commander, and how intelligently it can be processed at the very edge of the network," says James Hwang, President of Getac Technology Corporation. "Getac is evolving from a rugged device maker into a mission-critical platform provider, building an ecosystem where devices, software and connectivity work together across every domain. The MX60 and MX60W are an important step in that journey, bringing on-device intelligence and dependable interoperability into the hands of the individual soldier."

The MX60 and MX60W will be available from January 2027. For more information, please visit www.getac.com

About Getac

Getac Technology Corporation is a global leader in AI-capable rugged mobile technology and intelligent video solutions, including laptops, tablets, software, body-worn cameras, in-car video systems, digital evidence management and enterprise video analytics solutions. Getac's solutions and services are designed to enable extraordinary experiences for frontline workers in challenging environments. Today, Getac serves customers in over 100 countries spanning defence, public safety, ambulance, fire & rescue, utilities, automotive, natural resources, manufacturing, transport, and logistics. Getac was recognized as one of Newsweek's "World's Most Trustworthy Companies" for 2024. For more information, visit: https://www.getac.com. Participate in the Getac Industry blog or follow the company on LinkedIn and YouTube. 

Getac and Getac logo are trademarks of Getac Holdings Corporation or its affiliates. Qualcomm is a trademark or registered trademark of Qualcomm Incorporated. Qualcomm QCS6490 and Qualcomm AI Engine are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Arm is a registered trademark of Arm Limited (or its subsidiaries or affiliates) in the US and/or elsewhere. Android and Google Mobile Services are trademarks of Google LLC. Windows is a trademark of the Microsoft group of companies. Other brands or trademarks are the property of their respective owners. ©2026 Getac Technology Corporation.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Getac's New MX60 and MX60W Bring Mission-Critical Computing to Operators at the Tactical Edge

Getac's New MX60 and MX60W Bring Mission-Critical Computing to Operators at the Tactical Edge

Recommended Articles